** Gene therapy maker Bluebird Bio's BLUE.O shares rise 10% to $4.49 premarket
** BLUE said late on Friday it received a non-binding offer from privately held UK company Ayrmid for up to $110.5 million
** Ayrmid offered to acquire bluebird for $4.50 per share upfront, totaling about $43.8 million, according to Reuters calculations
** Ayrmid also offered an additional $6.84 per share, representing about $66.6 million, contingent upon bluebird achieving certain sales milestones
** In February, BLUE said it had agreed to be taken private by Carlyle Group <CG.O> and SK Capital Partners, for $3 per share upfront along with the same $6.84 per share, contingent upon it achieving certain sales milestones
** As of last close, BLUE has fallen 84% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。